Key Takeaways:
Intuitive Surgical Inc. (NASDAQ: ISRG) reported first-quarter revenue and earnings that significantly beat analyst expectations, but shares fell in after-hours trading as the company’s outlook for procedure growth pointed to a continued slowdown.
"Q1 was a solid start to the year for Intuitive, driven by 17% total procedure growth and broad-based adoption across da Vinci and Ion," Chief Executive Officer David Rosa said on the company’s earnings call.
The robotic surgery leader posted a 23% year-over-year increase in revenue to $2.77 billion, surpassing the consensus estimate of $2.62 billion. Adjusted earnings per share came in at $2.50, well ahead of the $2.12 analysts expected. Worldwide procedures grew 17 percent in the quarter.
The market reaction was driven by concerns that the company’s era of dominant growth may be moderating. Shares fell nearly 2% in late trading after the report, as investors weighed the updated guidance against a backdrop of increasing competition.
For the full year, Intuitive raised its forecast for da Vinci procedure growth to a range of 13.5% to 15.5%, up from a prior estimate of 13% to 15%. While an increase, the new range remains below the 18% growth achieved in 2025, signaling a deceleration that concerned investors.
The competitive landscape is intensifying, with established medical device firms Medtronic and Johnson & Johnson making inroads into the surgical robotics space. Johnson & Johnson, which is developing its own robot, has identified Intuitive as its primary competitor, adding pressure to Intuitive's long-held market dominance.
Intuitive placed 431 da Vinci systems in the first quarter, a 17% increase from the year-ago period. The placements included 232 of the company’s new da Vinci 5 systems, which received FDA clearance in March. The company also placed 52 of its Ion systems for lung biopsies.
Despite strong overall performance, management reiterated caution regarding international markets. CEO David Rosa noted "ongoing challenges in China and Japan," citing low tender activity and pricing pressure in China and capital constraints at public hospitals in Japan.
During the quarter, the company also managed a cyber incident which it stated did not disrupt business or manufacturing operations. It also announced that Chief Medical Officer Dr. Myriam Curet is retiring, to be succeeded by Dr. Jamie Wong.
The updated guidance suggests a transition for Intuitive Surgical from a period of hyper-growth to a more mature growth phase as it navigates a more competitive market. Investors will closely watch the adoption rate of the new da Vinci 5 system and its impact on margins in the company's second-quarter results.
This article is for informational purposes only and does not constitute investment advice.
